Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.

Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.
Br J Dermatol. 2020 Oct 24;:
Authors: Charvet E, Kramkimel N, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Sidibé T, Saiag P, Funck-Brentano E
Abstract
Cases of second primary cutaneous melanoma (SPCM), which were mostly BRAF-wild type, have been reported in BRAF-inhibitor-treated advanced cutaneous melanoma patients.1 Anti-programmed-death-receptor-1 (anti-PD-1) monoclonal antibodies (mAb) nivolumab and pembrolizumab have also revolutionized the prognosis of these patients, but 10-15% of them experience grade 3-4 adverse events according to Common Terminology Criteria for Adverse Events The risk of developing a SPCM in this population has not been reported and could be reduced by anti-PD-1 treatment.
PMID: 33098566 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - October 24, 2020 Category: Dermatology Authors: Charvet E, Kramkimel N, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Sidibé T, Saiag P, Funck-Brentano E Tags: Br J Dermatol Source Type: research